Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases

Molecular Endocrinology

Volumn 28, Issue 1, 2014, Pages 127-137

  Mullany, Lisa K ^a   Liu, Zhilin ^a   Wong, Kwong Kwok ^b   Deneke, Victoria ^a   Ren, Yi Athena ^a   Herron, Alan ^a   Richards, JoAnne S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; MATRIGEL; PROGESTERONE; PROTEIN P53; STEROID HORMONE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; IMMUNE SYSTEM; IMMUNOREGULATION; METASTASIS; MOUSE; NONHUMAN; NULL ALLELE; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; OVARY; PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891530938     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1308     Document Type: Article

References (25)

1. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol. 2009;4:287-313.
2. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:932371.
3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415-428.
4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
5. Hanrahan AJ, Schultz N, Westfal ML, et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012;2:56-67.
6. Scarlett UK, Rutkowski MR, Rauwerdink AM, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012;209:495-506.
7. Mullany LK, Liu Z, King ER, Wong KK, Richards JS. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology. 2012;153:1638-1648.
8. Mullany LK, Fan HY, Liu Z, et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene. 2011;30:3522-3536.
9. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-431.
10. Fan HY, Liu Z, Paquet M, et al. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res. 2009;69:6463-6472.
11. Beral V, Million Women Study Collaborators, Bull D, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369:1703-1710.
12. Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum-and taxane-resistant highgrade cancer of the ovary or peritoneum. Gynecol Oncol. 2008; 110:56-59.
13. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32-38.
14. Fan HY, Shimada M, Liu Z, et al. Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development. 2008;135:2127-2137.
15. Romero IL, Lee W, Mitra AK, et al. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012;124:134-141.
16. Schlumbrecht MP, Xie SS, Shipley GL, Urbauer DL, Broaddus RR. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum. Mod Pathol. 2011;24:453-462.
17. Langdon SP, Gabra H, Bartlett JM, et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res. 1998;4:2245-2251.
18. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11:411-423.
19. Laviolette LA, Garson K, Macdonald EA, et al. 17β-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology. 2010;151:929-938.
20. Spillman MA, Manning NG, Dye WW, et al. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010;70:8927-8936.
21. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22:255-288.
22. Trevino LS, Buckles EL, Johnson PA. Oral contraceptives decrease the prevalence of ovarian cancer in the hen. Cancer Prev Res (Phila). 2012;5:343-349.
23. Rasti M, Arabsolghar R, Khatooni Z, Mostafavi-Pour Z. p53 Binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol Oncol Res. 2012;18:169-175.
24. Akaogi K, Nakajima Y, Ito I, et al. KLF4 suppresses estrogendependent breast cancer growth by inhibiting the transcriptional activity of ERα. Oncogene. 2009;28:2894-2902.
25. Romero IL, Gordon IO, Jagadeeswaran S, et al. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009;2:792-799.